BCYC

Bicycle Therapeutics plc

22.99 USD
-0.04 (-0.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Bicycle Therapeutics plc stock is up 1.14% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 May’s closed higher than April. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Apr 15:31 17 May, 2024 25.00 CALL 223 0

About Bicycle Therapeutics plc

Bicycle Therapeutics plc develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema. BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT